ASSOCIATION BETWEEN THE SEROTONIN TRANSPORTER GENE AND AFFECTIVE DISORDER: THE EVIDENCE SO FAR

Alan D. Ogilvie and Anthony J. Harmar
MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, Edinburgh, United Kingdom

The serotonin transporter is one of a family of sodium-dependent monoamine transporters, which includes those for norepinephrine, dopamine, glycine, and GABA. Many antidepressant agents function by inhibiting the serotonin transporter, and the highly effective serotonin selective reuptake inhibitors (SSRIs), such as fluoxetine (Prozac), do so very specifically. In 1996 molecular genetic studies demonstrated an association between allelic variation in the gene for the serotonin transporter and susceptibility to affective disorder (depression and manic depressive illness), and they suggested that this gene may be important in determining the inheritance of certain "normal" personality traits, most notably, those grouped under the heading "neuroticism." In addition, the molecular biology of regulation of the serotonin transporter gene is beginning to be unravelled.

DYSFUNCTION OF THE SEROTONERGIC SYSTEM IN AFFECTIVE DISORDER

The serotonin transporter is a member of a very ancient family of proteins present in organisms ranging from bacteria to humans. Primitive members of this protein family probably evolved to enable cells to accumulate metabolically important small molecules or to respond to osmotic stress by intracellular accumulation of high concentrations of small organic solutes (osmolytes) in exchange for inorganic ions (electrolytes). In brain, similar proteins fulfill the more specialized function of terminating the action of neurotransmitters by removing them from the synaptic cleft and recycling them into the neurotransmitter pool.

The evidence for dysfunction of the serotonergic system in affective disorder is compelling. Levels of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) are decreased in depressed patients, especially those likely to commit suicide (reviewed in ref. 1). There is also evidence for reduced plasma levels of tryptophan, the amino acid precursor of serotonin, in depression (2,3), and tryptophan depletion causes a lowering of mood in normal subjects and in recovered depressed patients (4). In addition, withdrawal of L-tryptophan treatment appears to precipitate relapse in chronically depressed patients (5). Reports of abnormalities in the binding sites for imipramine in blood platelets and brain of patients (6,7) suggest altered function and/or regulation of the serotonin transporter in affective disorder. Imipramine was one of the first drugs used to effectively treat depressive illness (8,9). It is a tricyclic antidepressant that nonselectively inhibits the uptake of norepinephrine and serotonin. Serotonin selective reuptake inhibitors (SSRIs) such as fluoxetine, fluvoxetine, and paroxetine target the serotonin transporter specifically. These drugs were developed in a successful strategy to retain the efficacy of the tricyclic compounds, while reducing side effects and toxicity (10).
GENETIC VARIATION IN THE SEROTONIN TRANSPORTER

Following the cloning of the cDNA (11,12) encoding the human serotonin transporter, Lesch and colleagues (13) examined its primary structure in patients with affective disorder. Sequencing of the protein coding region failed to reveal changes in the deduced amino acid sequence, and only one base substitution, representing a silent polymorphism, was found in a single patient. Subsequent studies have focused on the role of polymorphisms in noncoding regions of the gene in the etiology of affective and related psychiatric disorders and in determining normal personality traits that may contribute to susceptibility to these disorders.

Polymorphism in Intron 2

The first polymorphic region described was a variable number tandem repeat (VNTR) in the second intron of the gene (14) that contains 9, 10, or 12 copies of a 16–17 bp motif (15) (Fig. 1). Although one report suggested that different allelic forms may exist in a non-Caucasian (Japanese) population (16), subsequent sequencing has not confirmed this (Battersby, Kunugi, Ogilvie et al., unpublished results). Several studies have now demonstrated an association between allelic forms at this locus and susceptibility to unipolar and to bipolar disorder. We have demonstrated an association between the rare 9 repeat form of the VNTR and risk of both unipolar (15) and bipolar disorder (17) in a Scottish population. This association was not found in German (18) or Japanese (16) patients, but subsequent studies have found an increased frequency of the 12 repeat allele in patients with bipolar disorder (19,20) in independent samples. This is also the case when the Japanese data is reconsidered in light of the correct sequence data (16). It is not clear whether allelic variation at this VNTR may directly influence expression of the transporter in the central nervous system (CNS) or whether this polymorphism is in linkage disequilibrium with a nearby locus of importance.

Polymorphism in the 5' Flanking Region

The second polymorphism of interest lies 1.2 kb upstream of the promoter of the gene where two relatively common allelic forms (528 bp “long” and 484 bp “short”) of a GC-rich repetitive sequence have been described (21) (Fig. 1). In vitro studies of the functional effects of this polymorphism in the context of the serotonin transporter promoter showed that the long variant is associated with a 3-fold higher transcriptional activity and increased responsiveness to stimulation by forskolin or phorbol ester. The long variant is also significantly more potent in repressing transcriptional activity when fused to a heterologous promoter. Serotonin transporter mRNA levels and serotonin uptake capacity were reduced in lymphoblastoid cell lines derived from individuals with one or two copies of the short allele compared with those from long homozygotes (22). A recent report (23) has shown that the short variant of the polymorphic region was significantly more frequent in patients with bipolar and unipolar affective disorder, which suggests that the polymorphism may have functional
consequences. In addition, it has been reported (24) that allelic variation at this locus correlates with anxiety-related personality traits, which may in turn be associated with increased risk of affective disorder (25). It thus remains to be estab-
lished whether this locus directly predisposes a person to affective disorder or does so indi-
crectly, mediating its effect by personality factors.

FUTURE DIRECTIONS

In summary, there is evidence to suggest that, in a subgroup of patients, a locus within or close to the serotonin transporter gene may predispose to affective disorder, either directly or as a conse-
quence of its effect on personality. There are two possible mechanisms that may explain the asso-
ciation between the two polymorphisms described above and the risk of affective disorder. It is
possible that the level of serotonin transporter gene transcription may be influenced by the se-
quen ces of the repetitive elements in either or both of the polymorphic regions. Alternatively, they may be in linkage disequilibrium with an-
other, more directly relevant gene locus. The fact that different allelic forms of the intron-2 pol-
ymorphism appear to be associated with affective disorder in different populations suggests linkage
disequilibrium with a nearby locus of biological significance. To assess the importance of the 5'
polyorphic region, studies of its influence on the expression and regulation of the serotonin
transporter gene in human subjects are required. Although it is clearly important to unravel the
biological consequences of these two polymorphisms, it is also plausible that the locus of impor-
tance lies elsewhere in the region. More detailed analysis of this region may ultimately yield
findings of great interest.

REFERENCES

3. DeMeyer MK, Shea PA, Hendrie HC, Yoshimura NN. (1981) Plasma tryptophan and five other amino acids in depressed and nor-
4. Salomon RM, Miller HL, Delgado PL, Char-
ney D. (1993) The use of tryptophan deple-
tion to evaluate central serotonin function in
depression and other neuropsychiatric disor-
5. Ferrier IN, Eccleston D, Moore PB, Wood
KA. (1990) Relapse in chronic depressives
on withdrawal of 1-tryptophan. Lancet 336:
380–381.
nin hypothesis: Necessary but not sufficient.
In: Feighner JP Boyer WF (eds.) Selective Ser-
ipramine binding in depressed patients re-
ceiving electroconvulsive therapy. Biol. Psy-
chiatry 24: 469.
9. Davis JM, Glassman AH. (1989) Antidepres-
10. Anderson IM, Tomenson BM. (1994) The
efficacy of selective serotonin re-uptake inhib-
itors in depression: A meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8: 238–249.
11. Lesch KP, Wolozin BL, Estler HC, Murphy
encoding the human brain serotonin trans-
al. (1993) Antidepressant- and cocaine-sen-
sitive human serotonin transporter: Mol-
13. Lesch KP, Gross J, Franzek E, Wolozin BL,
Riederer P, Murphy DL. (1995) Primary
structure of the serotonin transporter in
Organization of the human serotonin trans-
157–162.
(1996) A polymorphism of the serotonin
transporter gene is associated with suscepti-
bility to major affective disorder. Lancet 347:
731–733.
16. Kunugi H, Tatsumi M, Sakai T, Hattori M,


